Sintilimab plus chemotherapy for pediatric Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of the immunotherapy drug sintilimab with chemotherapy (AVD) for children and teens with newly diagnosed low- or intermediate-risk Hodgkin lymphoma. The goal is to see if adding sintilimab can improve outcomes while reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 1 to 18 years old.
- Newly diagnosed with classical Hodgkin lymphoma (not the lymphocyte-predominant type).
- Disease is at a low- or intermediate-risk stage (stage I, II, or certain stage III cases).
- Has at least one measurable tumor lesion.
- No prior cancer treatment for this lymphoma.
- Adequate organ function and overall health (Lansky or Karnofsky score at least 50).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
This trial tests a drug called tislelizumab (an immunotherapy that helps your immune system fight cancer) added to standard chemotherapy for older adults with newly diagnosed Hodgkin lymphoma. The goal is to see if adding this drug improves outcomes without too many side effects.
This study tests a combination of a newer immunotherapy drug (nivolumab) with standard chemotherapy (AVD) in children, teens, and young adults with newly diagnosed, early-stage Hodgkin lymphoma—a blood cancer affecting lymph nodes. The goal is to see if adding immunotherapy improves outcomes while being tolerable for this age group.
This trial studies a treatment plan for children with classical Hodgkin lymphoma that uses lower total doses of chemotherapy and reduced radiation. The goal is to help control the lymphoma while lowering long-term side effects.
This trial tests a new combination of two drugs—a PD-1 antibody and a JAK1 inhibitor—for children and teens with newly diagnosed Hodgkin lymphoma. The goal is to see if this combination can help treat the cancer more effectively.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.